Therapeutic antibodies sits at the center of this dementia and brain health question.

Yes, therapeutic antibodies designed to target amyloid-beta and tau proteins are advancing through Alzheimer’s drug development with genuine momentum. The FDA approved two anti-amyloid monoclonal antibodies in the past two years—lecanemab in January 2023 and donanemab in July 2024—marking the first disease-modifying treatments that measurably slow cognitive decline in early-stage Alzheimer’s disease. These aren’t breakthrough cures, but they represent a meaningful shift in how neurologists approach early symptomatic and preclinical Alzheimer’s disease, offering patients a way to slow the rate of cognitive loss by approximately 30–35% over 12–18 months of treatment.

This article explores how these antibody-based therapies work, what the clinical evidence shows, which patients benefit most, the safety trade-offs you should understand, and what comes next in the drug pipeline. The field is moving beyond these initial approvals. Researchers have finally uncovered the precise mechanism that makes these therapies effective—the “Fc fragment” of these antibodies activates the brain’s own immune cells, called microglia, to clear harmful amyloid deposits. Multiple next-generation candidates are in late-stage trials, including tau-targeting antibodies with Fast Track FDA status and innovative new delivery technologies designed to cross the blood-brain barrier more efficiently.

How Do Anti-Amyloid Monoclonal Antibodies Clear Alzheimer’s Pathology?
What Clinical Results Prove These Antibodies Slow Cognitive Decline?
What Are the Safety Trade-Offs and Why Does ARIA Matter?
Which Patients Should Receive These Antibodies—Is One Better Than the Other?
What Happened to Earlier Anti-Amyloid Antibodies and Why Should Patients Care?
What Next-Generation Antibodies Are in Development?
What Does the Future of Alzheimer’s Immunotherapy Look Like?
Conclusion

How Do Anti-Amyloid Monoclonal Antibodies Clear Alzheimer’s Pathology?

Monoclonal antibodies work by binding to amyloid-beta proteins that accumulate in Alzheimer’s disease and marking them for destruction. When these antibodies attach to amyloid deposits, they activate the brain’s resident immune cells—microglia—which then engulf and clear the plaques. This mechanism was only recently clarified in 2025 research from ScienceDaily, which showed that the Fc fragment (the constant region of the antibody) is the critical component that tells microglia to attack the amyloid. Without proper Fc-mediated activation, the antibody just binds amyloid without clearing it efficiently, which is why older or poorly designed antibodies failed in clinical trials. Lecanemab (brand name Leqembi) and donanemab (brand name Kisunla) both use this mechanism.

Lecanemab was developed by Eli Lilly and Biogen, while donanemab is an Eli Lilly product. The key difference isn’t just their chemical structure—it’s their pharmacokinetics and the way they distribute in the cerebrospinal fluid. Lecanemab requires infusions every two weeks, whereas donanemab uses an infusion schedule that transitions to lower maintenance doses over time, potentially offering more convenience for patients. Neither antibody crosses the blood-brain barrier passively; instead, they rely on specialized transport mechanisms or low-dose delivery to achieve adequate brain penetration. Older approaches failed because they relied on amyloid sequestration alone—trapping the amyloid without activating immune clearance—and because many compounds couldn’t reach the brain in sufficient concentrations. The current generation overcomes these barriers through careful Fc engineering and formulation optimization.

How Do Anti-Amyloid Monoclonal Antibodies Clear Alzheimer's Pathology?

What Clinical Results Prove These Antibodies Slow Cognitive Decline?

Both lecanemab and donanemab reduced cognitive decline by approximately 30% over 12–18 months of continuous treatment in phase III clinical trials. Donanemab specifically showed a 35% delay in cognitive decline as measured on the iADRS (Integrated Alzheimer’s Disease Rating Scale), a composite measure that captures both cognitive and functional decline. This means a patient who would typically lose the ability to manage a household chore within 4 months might retain that ability for 5.4 months on donanemab. The difference is clinically meaningful but not dramatic—patients still experience decline; the treatment slows the rate. These efficacy results apply only to people with mild cognitive impairment or mild dementia due to Alzheimer’s disease who have documented amyloid pathology on PET imaging or CSF biomarkers.

Patients with moderate to severe dementia were excluded from trials and are not candidates for these therapies. The trials also required sustained adherence: lecanemab infusions every two weeks for the entire study period, and donanemab infusions on a fixed schedule. Real-world adherence will likely be lower than in controlled trials, which could reduce the observed benefit. However, if a patient achieves the targeted amyloid reduction (measured by PET imaging), the cognitive slowing is reasonably consistent across age groups and baseline cognitive severity (within the mild range). This consistency suggests the mechanism is robust, not dependent on lucky patient selection.

What Are the Safety Trade-Offs and Why Does ARIA Matter?

The major safety concern with anti-amyloid antibodies is amyloid-related imaging abnormalities (ARIA)—a radiological finding that includes brain edema (ARIA-E) and microhemorrhages (ARIA-H). Treated patients experience ARIA approximately 4.35 times more frequently than control patients. ARIA-E manifests on MRI as swelling in the brain parenchyma, sometimes accompanied by headaches, confusion, or gait disturbance. ARIA-H appears as tiny bleeds on susceptibility-weighted MRI sequences and can be asymptomatic. Donanemab carries a higher risk of ARIA-E than lecanemab, which is a critical safety distinction.

Some patients tolerate ARIA-E and continue treatment without clinical symptoms, while others develop encephalopathy requiring hospitalization and discontinuation of the drug. In published trials, symptomatic ARIA-E occurred in 2–3% of lecanemab recipients and higher in donanemab recipients, particularly among APOE ε4 carriers (people who carry the high-risk Alzheimer’s gene variant). Patients with two copies of APOE ε4 (ε4 homozygotes) have substantially higher ARIA rates and are often considered less suitable candidates for these therapies. The practical implication: before starting either lecanemab or donanemab, patients should undergo baseline MRI to rule out microinfarcts or previous microhemorrhages, and genotyping for APOE status is increasingly recommended for precision patient selection. Patients must commit to monthly MRI monitoring for the first year of treatment and understand that if they develop symptomatic ARIA, the infusion must stop immediately.

What Are the Safety Trade-Offs and Why Does ARIA Matter?

Which Patients Should Receive These Antibodies—Is One Better Than the Other?

Patient selection relies on three criteria: (1) amyloid positivity confirmed by PET, CSF phosphorylated-tau, or blood biomarkers (phospho-tau-181 or phospho-tau-217); (2) mild cognitive impairment or mild dementia due to Alzheimer’s disease; and (3) low APOE ε4 burden (ideally 0 or 1 copy; homozygotes require careful discussion of risk-benefit). APOE ε4 status is not an absolute contraindication, but it substantially increases the probability of ARIA, which is why precision patient selection is recommended. Between lecanemab and donanemab, lecanemab has a better safety profile regarding ARIA-E and may be preferable for patients with higher APOE ε4 burden or those who can tolerate only lower risk. Donanemab has stronger efficacy (35% vs. 30% decline slowing), which may outweigh its higher ARIA-E risk in younger patients with early-onset disease or those willing to accept closer MRI monitoring.

The infusion schedule also matters: lecanemab requires every-two-weeks dosing, while donanemab allows for longer intervals after the induction phase. For patients with transportation or access barriers, donanemab’s less frequent infusions may improve real-world adherence. One practical limitation: insurance coverage and prior authorization requirements vary widely. Some payers restrict these therapies to specific criteria or require failure of other treatments first. The newest autoinjector formulation for lecanemab (subcutaneous weekly maintenance) is not yet widely available but could significantly improve convenience once approved, potentially shifting the lecanemab-versus-donanemab calculus.

What Happened to Earlier Anti-Amyloid Antibodies and Why Should Patients Care?

Aducanumab (Aduhelm), approved by the FDA in 2020 under accelerated review, was withdrawn from the market in 2024 because of limited clinical uptake and controversial efficacy-risk balance. Although aducanumab showed biomarker changes in early trials, the clinical benefit was never clearly demonstrated, and safety concerns arose. Aducanumab’s failure is important context: it shows that FDA approval doesn’t guarantee a therapy will prove safe or effective in routine practice.

Patients or families who may have read about aducanumab in the news should understand that lecanemab and donanemab have much stronger clinical evidence behind them and were not approved under accelerated pathways. Other antibodies in earlier development failed because they lacked the proper Fc engagement or couldn’t reach the brain in sufficient concentrations. These failures drove the mechanism discoveries that made lecanemab and donanemab possible. The lesson is that not all antibody designs work, and the specific engineering of the Fc fragment matters tremendously.

What Happened to Earlier Anti-Amyloid Antibodies and Why Should Patients Care?

What Next-Generation Antibodies Are in Development?

Two particularly promising candidates are advancing through late-stage trials. Trontinemab, developed by Roche, uses a proprietary “Brainshuttle” technology—essentially, the amyloid-targeting antibody is fused to a transferrin receptor shuttle that enables it to cross the blood-brain barrier at very low doses. This approach could reduce systemic side effects and allow lower, less frequent dosing. Roche plans to initiate Phase III trials for trontinemab in 2025 in both early symptomatic and preclinical Alzheimer’s disease (asymptomatic people with amyloid pathology). If successful, trontinemab could become available by 2027–2028.

Posdinemab takes a different approach: instead of targeting amyloid-beta, it targets phosphorylated tau, a different pathological protein in Alzheimer’s disease. The FDA granted posdinemab Fast Track designation in January 2025, expediting its development pathway. The AuTonomy Phase 2b study is ongoing for early Alzheimer’s disease treatment. Tau-targeting therapies address a different part of the pathological cascade and could be used alone or in combination with amyloid-targeted treatments in the future. The potential for combination therapy—anti-amyloid plus anti-tau—is one reason the field is progressing rapidly.

What Does the Future of Alzheimer’s Immunotherapy Look Like?

The trajectory suggests a shift toward combination therapy, precision dosing, and biomarker-directed treatment. Within the next 2–3 years, neurologists will likely treat amyloid-positive, early-stage Alzheimer’s disease with both amyloid and tau-targeting antibodies simultaneously, much as oncologists combine multiple immunotherapy agents. This multi-target approach addresses the fact that both amyloid and tau contribute to neurodegeneration.

The discovery of the Fc fragment’s role in microglial activation has also opened the door to engineered antibodies with optimized immune engagement—versions that clear amyloid more efficiently or activate different brain immune pathways. Subcutaneous and even oral formulations are in development, which could move treatments out of infusion centers and into primary care or home-based administration. These advances will substantially improve access and adherence, particularly for patients in underserved areas.

Conclusion

Therapeutic antibodies targeting amyloid-beta and tau are meaningfully advancing Alzheimer’s disease treatment. Lecanemab and donanemab, now approved and in clinical use, slow cognitive decline by 30–35% in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease—a meaningful but not dramatic effect. The safety trade-off is amyloid-related imaging abnormalities, particularly brain edema, which requires baseline and ongoing MRI monitoring and patient selection based on APOE genotype.

The next wave of therapies—including Roche’s Brainshuttle-enabled trontinemab and tau-targeting posdinemab—promises better brain penetration, lower dosing, fewer adverse events, and the possibility of combination therapy. Patients and caregivers considering these treatments should understand that they apply only to early stages of disease, require commitment to regular infusions and imaging, and work best when combined with careful patient selection. Speak with a neurologist about amyloid testing and APOE genotyping to determine candidacy.